查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914720

頭頸癌治療市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、診斷方法、治療方法、疾病適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Head and Neck Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Type, By Diagnostic Methods, By Treatment Type, By Disease Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球頭頸癌治療市場預計將從 2025 年的 23.8 億美元大幅成長至 2031 年的 49.1 億美元，複合年成長率達 12.83%。

此領域涵蓋多種藥物治療方案，包括化療、免疫療法和標靶治療，這些方案均是專門針對口腔、咽喉和喉部惡性腫瘤而開發的。推動該市場發展的主要因素是這些癌症發生率的上升，而這主要是由吸煙和飲酒等風險因素造成的。根據美國癌症協會估計，2024年美國將新增約58,450例口腔癌和咽喉癌病例，凸顯了日益嚴重的疾病負擔，也凸顯了對有效治療方案的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 23.8億美元
市場規模：2031年 49.1億美元
複合年成長率：2026-2031年 12.83%
成長最快的細分市場 喉癌
最大的市場 北美洲

然而，新核准的生物製藥和免疫療法價格高昂，成為市場發展的一大障礙。這種經濟負擔限制了病患的用藥機會，並減緩了藥物的普及速度，尤其是在醫療保險體系薄弱的開發中國家，這阻礙了整體市場的成長潛力。

市場促進因素

免疫查核點抑制劑和PD-1/PD-L1拮抗劑的迅速應用從根本上改變了頭頸部鱗狀細胞癌（HNSCC）的治療模式。這些生物製藥已從二線治療方案發展成為標準療法，由於其對轉移性疾病的高效性，它們取代或補充了傳統的鉑類化療。這種治療方法的演變體現在行業領導者的財務成功上。根據默克公司於2024年2月發布的2023年度報告，PD-1療法Keytruda的銷售額預計將成長19%，達到250億美元，這一成長部分歸因於全球對頭頸癌治療的持續需求。免疫療法的廣泛應用透過建立高溢價和延長患者生存期提高了市場價值，但也導致與傳統通訊協定相比，治療療程需要延長。

同時，HPV相關口咽癌發生率的不斷上升正在重塑市場格局，催生出一個獨特且不斷擴大的患者群體。這種流行病學轉變的促進因素是預防性醫療服務的缺失，導致相當一部分人群易受此類惡性腫瘤的侵襲。根據美國臨床腫瘤學會（ASCO）在2024年6月舉行的年會上發布的一項調查，截至2022年，僅有不到60%的青少年接種了人類乳突病毒(HPV)疫苗，這意味著許多人仍然面臨著未來患有HPV感染相關癌症的高風險。鑑於需要新的治療方法來應對這種不斷變化的疾病負擔，投資者正向該行業投入大量資金。例如，根據2024年5月發布的題為「Bicycle Therapeutics完成5.55億美元私募融資」的新聞稿，該公司籌集了5.55億美元，用於推進其針對腫瘤（包括頭頸癌）的精準治療藥物的臨床研發。

市場挑戰

新核准的生物製藥和免疫療法的高昂成本嚴重阻礙了全球頭頸癌治療市場的成長。儘管這些先進的藥物干預措施能夠改善臨床療效，但其高昂的價格造成了沉重的經濟負擔，限制了患者的用藥機會，並阻礙了市場滲透。在許多地區，尤其是在醫療預算有限或健保報銷體係不完善的地區，這種經濟負擔迫使醫療服務提供者優先選擇傳統的低成本療法，而非新型藥物。這種價格差距直接減少了符合高價療法條件的患者數量，導致新藥普及率停滯不前，製造商的收入成長也受到限制。

治療過程中產生的高昂費用凸顯了這項經濟挑戰的嚴峻。根據美國耳鼻喉頭頸外科學會 (AAO-HNS) 2024 年的報告，頭頸癌患者的治療費用中位數估計為 79,151 美元，遠高於許多其他惡性腫瘤。如此高的費用結構阻礙了最先進治療的廣泛應用。高額的自付費用和不足的保險覆蓋範圍使得大量患者無法獲得治療。因此，這些先進治療方法的經濟可行性成為其廣泛應用的一大障礙，阻礙了市場充分發揮其潛力。

市場趨勢

新型聯合治療的出現對市場產生了重大影響，尤其是那些將雙特異性抗體與已上市的免疫查核點抑制劑聯合使用以增強臨床療效的療法。透過同時針對多個致癌通路，例如 EGFR 和 LGR5，這種治療方法策略旨在克服單藥療法固有的抗藥性機制，並改善復發或轉移性疾病的治療效果。根據 Merus NV 公司於 2024 年 5 月 24 日發布的題為「Merus 公司關於 Petsemtamab和 Pembrolizumab一線頭頸部鱗狀細胞癌聯合治療的摘要Pembrolizumab2024 年 ASCO 年會接收進行口頭報告」的新聞稿，該臨床實驗聯合治療療法在可評估的患者中顯示出 67% 的聯合聯合治療，聯合治療通訊協定。

同時，市場正在探索以沙粒病毒為基礎的治療性疫苗，這些疫苗能夠誘發針對HPV陽性惡性腫瘤的強效T細胞反應。這一趨勢標誌著治療方向正轉向主動免疫療法，即利用新型載體平台將腫瘤特異性抗原直接遞送至免疫系統，從而增強標準PD-1抑制劑的療效。根據HOOKIPA Pharma Inc.於2024年6月發布的題為「HOOKIPA Pharma在2024年美國臨床腫瘤學會年會上公佈II期臨床試驗最新數據」的新聞稿，該公司免疫治療藥物HB-200與Pembrolizumab的聯合治療在PD-L1聯合評分≥20的患者中取得了53%的客觀確認緩解率。這項進展體現了業界致力於精準醫療干預病毒驅動型癌症的決心。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球頭頸癌藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（診斷方法、治療類型）
    • 依診斷方法（切片檢查、影像診斷、內視鏡檢查、其他）
    • 依治療方法（手術、放射線治療、化療、免疫療法、分子標靶療法）
    • 依疾病指徵（唇癌及口腔癌、喉癌、口咽癌、唾液腺癌、鼻咽癌、下嚥癌）
    • 給藥途徑（注射、口服）
    • 治療分類（PD抑制劑、EGFR抑制劑、微管抑制劑）
    • 依最終使用者（醫院、專科診所、門診手術中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美頭頸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲頭頸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區頭頸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲頭頸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲頭頸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球頭頸癌藥物市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lilly and Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Pfizer Inc.
  • Sanofi SA
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5056

The Global Head and Neck Cancer Therapeutics Market is projected to expand significantly, rising from USD 2.38 Billion in 2025 to USD 4.91 Billion by 2031, reflecting a compound annual growth rate of 12.83%. This sector comprises various pharmaceutical interventions, including chemotherapies, immunotherapies, and targeted agents, specifically developed to address malignancies affecting the oral cavity, pharynx, and larynx. The principal force propelling this market forward is the escalating incidence of these cancers, primarily driven by risk factors such as tobacco usage and alcohol consumption. According to the 'American Cancer Society', in '2024', an estimated 58,450 new cases of oral cavity and pharynx cancer were diagnosed in the United States, highlighting the increasing disease burden that necessitates the demand for effective treatment solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.38 Billion
Market Size 2031USD 4.91 Billion
CAGR 2026-203112.83%
Fastest Growing SegmentLaryngeal Cancer
Largest MarketNorth America

However, the market encounters a substantial obstacle regarding the prohibitive expense of newly approved biologics and immunotherapies. This financial strain limits patient access and slows adoption rates, especially in developing countries where healthcare reimbursement structures are restricted, thereby hindering the overall potential for market growth.

Market Driver

The swift integration of immune checkpoint inhibitors and PD-1/PD-L1 antagonists has radically transformed the treatment landscape for head and neck squamous cell carcinoma (HNSCC). These biologic agents have advanced from being second-line alternatives to becoming standard-of-care therapies, effectively supplanting or complementing traditional platinum-based chemotherapies because of their enhanced efficacy in metastatic scenarios. This therapeutic evolution is quantitatively demonstrated by the financial success of industry leaders; according to Merck & Co., Inc., February 2024, in the '2023 Annual Report', sales of the PD-1 therapy Keytruda increased by 19% to $25.0 billion, a rise linked partially to continued global demand for treating head and neck cancer. The broad adoption of immunotherapies boosts market value by establishing premium pricing and prolonging patient survival, which subsequently requires extended treatment durations relative to conventional protocols.

At the same time, the market is being redefined by the increasing prevalence of HPV-associated oropharyngeal cancers, resulting in a distinct and growing patient demographic. This epidemiological shift is driven by deficiencies in preventative care that leave significant portions of the population vulnerable to these malignancies. According to the American Society of Clinical Oncology (ASCO), June 2024, research presented at the '2024 Annual Meeting' emphasized that fewer than 60% of adolescents had received the HPV vaccine in 2022, suggesting a lingering pool of high-risk individuals prone to future infection-related cancers. Acknowledging the necessity for new modalities to manage this changing disease burden, investors are directing substantial funds into the industry. For example, according to Bicycle Therapeutics, May 2024, in the press release 'Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing', the firm obtained $555 million to further its clinical pipeline of precision-guided therapeutics for oncology conditions, including head and neck cancer.

Market Challenge

The prohibitive costs associated with newly approved biologics and immunotherapies present a substantial barrier to the growth of the Global Head and Neck Cancer Therapeutics Market. While these advanced pharmaceutical interventions offer improved clinical outcomes, their high price points create severe financial toxicity that restricts patient access and limits market penetration. In many regions, particularly those with constrained healthcare budgets or underdeveloped reimbursement frameworks, the economic burden forces healthcare providers to prioritize conventional, lower-cost treatments over novel agents. This affordability gap directly reduces the addressable patient population for premium therapeutics, thereby stalling adoption rates and curbing revenue expansion for manufacturers.

The magnitude of this financial challenge is evidenced by the elevated expenses incurred during care. According to the 'American Academy of Otolaryngology-Head and Neck Surgery', in '2024', the median treatment cost for patients with head and neck cancer was found to be $79,151, a figure significantly higher than that for many other malignancies. This exorbitant cost structure discourages the widespread prescription of cutting-edge therapies, as high out-of-pocket expenditures and insufficient insurance coverage render them inaccessible for a large demographic. Consequently, the market fails to realize its full potential, as the economic feasibility of these sophisticated treatments remains a critical impediment to broader utilization.

Market Trends

The emergence of novel combination therapies is significantly influencing the market, particularly through the pairing of bispecific antibodies with established immune checkpoint inhibitors to enhance clinical efficacy. This therapeutic strategy aims to overcome resistance mechanisms inherent in monotherapies by simultaneously targeting multiple oncogenic pathways, such as EGFR and LGR5, thereby improving outcomes in recurrent or metastatic settings. According to Merus N.V., May 2024, in the press release 'Merus Announces Abstract on Petosemtamab in Combination with Pembrolizumab in 1L HNSCC Selected for Oral Presentation at 2024 ASCO Annual Meeting', the investigational combination demonstrated a 67% objective response rate in evaluable patients, highlighting the superior performance of these multi-modal regimens compared to traditional single-agent protocols.

Simultaneously, the market is characterized by the exploration of arenaviral-based therapeutic vaccines designed to elicit robust T-cell responses against HPV-positive malignancies. This trend represents a shift toward active immunotherapy, where novel vector platforms are employed to deliver tumor-specific antigens directly to the immune system, potentiating the effects of standard PD-1 blockade. According to HOOKIPA Pharma Inc., June 2024, in the press release 'HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting', the combination of their immunotherapy HB-200 with pembrolizumab yielded a confirmed objective response rate of 53% in patients with a PD-L1 combined positive score of 20 or higher. This development illustrates the industry's commitment to precision-guided interventions for virally driven cancers.

Key Market Players

  • Eli Lilly and Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Head and Neck Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Head and Neck Cancer Therapeutics Market, By Type

  • Diagnostic Methods
  • Treatment Type

Head and Neck Cancer Therapeutics Market, By Diagnostic Methods

  • Biopsy
  • Imaging
  • Endoscopy
  • Others

Head and Neck Cancer Therapeutics Market, By Treatment Type

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

Head and Neck Cancer Therapeutics Market, By Disease Indication

  • Lip and Oral Cavity Cancer
  • Laryngeal Cancer
  • Oropharyngeal Cancer
  • Salivary Gland Cancer
  • Nasopharyngeal Cancer
  • Hypopharyngeal Cancer

Head and Neck Cancer Therapeutics Market, By Route of Administration

  • Injectable
  • Oral

Head and Neck Cancer Therapeutics Market, By Therapeutic Class

  • PD Inhibitors
  • EGFR Inhibitors
  • Microtubule Inhibitors

Head and Neck Cancer Therapeutics Market, By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Head and Neck Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Head and Neck Cancer Therapeutics Market.

Available Customizations:

Global Head and Neck Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Head and Neck Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Methods, Treatment Type)
    • 5.2.2. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
    • 5.2.3. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
    • 5.2.4. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
    • 5.2.5. By Route of Administration (Injectable, Oral)
    • 5.2.6. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
    • 5.2.7. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.8. By Region
    • 5.2.9. By Company (2025)
  • 5.3. Market Map

6. North America Head and Neck Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnostic Methods
    • 6.2.3. By Treatment Type
    • 6.2.4. By Disease Indication
    • 6.2.5. By Route of Administration
    • 6.2.6. By Therapeutic Class
    • 6.2.7. By End User
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Head and Neck Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnostic Methods
        • 6.3.1.2.3. By Treatment Type
        • 6.3.1.2.4. By Disease Indication
        • 6.3.1.2.5. By Route of Administration
        • 6.3.1.2.6. By Therapeutic Class
        • 6.3.1.2.7. By End User
    • 6.3.2. Canada Head and Neck Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnostic Methods
        • 6.3.2.2.3. By Treatment Type
        • 6.3.2.2.4. By Disease Indication
        • 6.3.2.2.5. By Route of Administration
        • 6.3.2.2.6. By Therapeutic Class
        • 6.3.2.2.7. By End User
    • 6.3.3. Mexico Head and Neck Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnostic Methods
        • 6.3.3.2.3. By Treatment Type
        • 6.3.3.2.4. By Disease Indication
        • 6.3.3.2.5. By Route of Administration
        • 6.3.3.2.6. By Therapeutic Class
        • 6.3.3.2.7. By End User

7. Europe Head and Neck Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnostic Methods
    • 7.2.3. By Treatment Type
    • 7.2.4. By Disease Indication
    • 7.2.5. By Route of Administration
    • 7.2.6. By Therapeutic Class
    • 7.2.7. By End User
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnostic Methods
        • 7.3.1.2.3. By Treatment Type
        • 7.3.1.2.4. By Disease Indication
        • 7.3.1.2.5. By Route of Administration
        • 7.3.1.2.6. By Therapeutic Class
        • 7.3.1.2.7. By End User
    • 7.3.2. France Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnostic Methods
        • 7.3.2.2.3. By Treatment Type
        • 7.3.2.2.4. By Disease Indication
        • 7.3.2.2.5. By Route of Administration
        • 7.3.2.2.6. By Therapeutic Class
        • 7.3.2.2.7. By End User
    • 7.3.3. United Kingdom Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnostic Methods
        • 7.3.3.2.3. By Treatment Type
        • 7.3.3.2.4. By Disease Indication
        • 7.3.3.2.5. By Route of Administration
        • 7.3.3.2.6. By Therapeutic Class
        • 7.3.3.2.7. By End User
    • 7.3.4. Italy Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnostic Methods
        • 7.3.4.2.3. By Treatment Type
        • 7.3.4.2.4. By Disease Indication
        • 7.3.4.2.5. By Route of Administration
        • 7.3.4.2.6. By Therapeutic Class
        • 7.3.4.2.7. By End User
    • 7.3.5. Spain Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnostic Methods
        • 7.3.5.2.3. By Treatment Type
        • 7.3.5.2.4. By Disease Indication
        • 7.3.5.2.5. By Route of Administration
        • 7.3.5.2.6. By Therapeutic Class
        • 7.3.5.2.7. By End User

8. Asia Pacific Head and Neck Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnostic Methods
    • 8.2.3. By Treatment Type
    • 8.2.4. By Disease Indication
    • 8.2.5. By Route of Administration
    • 8.2.6. By Therapeutic Class
    • 8.2.7. By End User
    • 8.2.8. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnostic Methods
        • 8.3.1.2.3. By Treatment Type
        • 8.3.1.2.4. By Disease Indication
        • 8.3.1.2.5. By Route of Administration
        • 8.3.1.2.6. By Therapeutic Class
        • 8.3.1.2.7. By End User
    • 8.3.2. India Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnostic Methods
        • 8.3.2.2.3. By Treatment Type
        • 8.3.2.2.4. By Disease Indication
        • 8.3.2.2.5. By Route of Administration
        • 8.3.2.2.6. By Therapeutic Class
        • 8.3.2.2.7. By End User
    • 8.3.3. Japan Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnostic Methods
        • 8.3.3.2.3. By Treatment Type
        • 8.3.3.2.4. By Disease Indication
        • 8.3.3.2.5. By Route of Administration
        • 8.3.3.2.6. By Therapeutic Class
        • 8.3.3.2.7. By End User
    • 8.3.4. South Korea Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnostic Methods
        • 8.3.4.2.3. By Treatment Type
        • 8.3.4.2.4. By Disease Indication
        • 8.3.4.2.5. By Route of Administration
        • 8.3.4.2.6. By Therapeutic Class
        • 8.3.4.2.7. By End User
    • 8.3.5. Australia Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnostic Methods
        • 8.3.5.2.3. By Treatment Type
        • 8.3.5.2.4. By Disease Indication
        • 8.3.5.2.5. By Route of Administration
        • 8.3.5.2.6. By Therapeutic Class
        • 8.3.5.2.7. By End User

9. Middle East & Africa Head and Neck Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnostic Methods
    • 9.2.3. By Treatment Type
    • 9.2.4. By Disease Indication
    • 9.2.5. By Route of Administration
    • 9.2.6. By Therapeutic Class
    • 9.2.7. By End User
    • 9.2.8. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnostic Methods
        • 9.3.1.2.3. By Treatment Type
        • 9.3.1.2.4. By Disease Indication
        • 9.3.1.2.5. By Route of Administration
        • 9.3.1.2.6. By Therapeutic Class
        • 9.3.1.2.7. By End User
    • 9.3.2. UAE Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnostic Methods
        • 9.3.2.2.3. By Treatment Type
        • 9.3.2.2.4. By Disease Indication
        • 9.3.2.2.5. By Route of Administration
        • 9.3.2.2.6. By Therapeutic Class
        • 9.3.2.2.7. By End User
    • 9.3.3. South Africa Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnostic Methods
        • 9.3.3.2.3. By Treatment Type
        • 9.3.3.2.4. By Disease Indication
        • 9.3.3.2.5. By Route of Administration
        • 9.3.3.2.6. By Therapeutic Class
        • 9.3.3.2.7. By End User

10. South America Head and Neck Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnostic Methods
    • 10.2.3. By Treatment Type
    • 10.2.4. By Disease Indication
    • 10.2.5. By Route of Administration
    • 10.2.6. By Therapeutic Class
    • 10.2.7. By End User
    • 10.2.8. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnostic Methods
        • 10.3.1.2.3. By Treatment Type
        • 10.3.1.2.4. By Disease Indication
        • 10.3.1.2.5. By Route of Administration
        • 10.3.1.2.6. By Therapeutic Class
        • 10.3.1.2.7. By End User
    • 10.3.2. Colombia Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnostic Methods
        • 10.3.2.2.3. By Treatment Type
        • 10.3.2.2.4. By Disease Indication
        • 10.3.2.2.5. By Route of Administration
        • 10.3.2.2.6. By Therapeutic Class
        • 10.3.2.2.7. By End User
    • 10.3.3. Argentina Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnostic Methods
        • 10.3.3.2.3. By Treatment Type
        • 10.3.3.2.4. By Disease Indication
        • 10.3.3.2.5. By Route of Administration
        • 10.3.3.2.6. By Therapeutic Class
        • 10.3.3.2.7. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Head and Neck Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. AstraZeneca plc
  • 15.6. Pfizer Inc.
  • 15.7. Sanofi S.A.
  • 15.8. Novartis AG
  • 15.9. Amgen Inc.
  • 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer